longevity researchGLP-1 Drugs and Longevity in Men: What the Evidence Actually Shows

In July 2025, a 32-week randomized controlled trial reported that semaglutide slowed the pace of biological aging by approximately 9% on the DunedinPACE epigenetic clock. The paper made headlines in longevity circles. Peter Attia mentioned it. Huberman mentioned it. A dozen longevity newsletters ran it as confirmation that GLP-1 drugs belong in any serious anti-aging stack.

What almost nobody mentioned: the trial was conducted in adults with HIV-associated lipohypertrophy — a population whose antiretroviral therapy produces pathologically accelerated aging and profoundly dysregulated fat metabolism. These were not healthy men optimizing performance. They were patients whose biology had been systematically altered by a decades-long viral infection and its pharmacological management.

This distinction matters enormously. Here is an honest account of what the evidence actually shows — and for whom it shows it.

The Cardiovascular Signal: The Strongest Case for GLP-1s#

Set aside the epigenetic clock data for a moment. The most rigorous and actionable longevity evidence for semaglutide comes from cardiovascular outcomes, not aging clocks.

The SELECT trial enrolled 17,604 adults with overweight or obesity and preexisting cardiovascular disease but no diabetes. After approximately 33 months of semaglutide 2.4 mg weekly, the drug produced a 20% reduction in major adverse cardiovascular events — the composite endpoint of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke.

This is a genuinely large effect size for a cardiovascular intervention. For context, statins typically produce 25–35% relative risk reduction in MACE in similar populations after years of treatment. Semaglutide, in less than three years, matched the lower end of that range. And the cardiovascular benefit appeared to exceed what you would predict from weight loss alone — suggesting direct vascular, inflammatory, and metabolic mechanisms beyond adiposity reduction.

The mechanistic picture fits. GLP-1 receptor agonists reduce hsCRP (a marker of systemic inflammation), improve endothelial function, lower systolic blood pressure by 3–5 mmHg, reduce ApoB-containing lipoproteins, and appear to directly stabilize atherosclerotic plaques through anti-inflammatory signaling in the vascular wall. These are not weight-loss artifacts — they are pharmacological effects observable at the tissue level.

Where the SELECT data becomes complicated: the population had preexisting CV disease. SELECT is not a primary prevention trial. Extrapolating its 20% MACE reduction to a 35-year-old man with clean bloodwork and no cardiac history is inference, not evidence. The cardiovascular benefit is likely smaller in lower-risk men — a common statistical property of risk-reduction interventions that becomes invisible in absolute terms when baseline risk is low.

The Epigenetic Clock Data: Genuine Signal, Wrong Population#

Now back to the study that generated the headlines.

The 32-week phase 2b trial in HIV-associated lipohypertrophy found that semaglutide slowed DunedinPACE by ~9% and reversed PhenoAge by approximately 4.9 years. These are substantial numbers on clocks that have been validated against downstream health outcomes including cancer risk, cardiovascular disease, and all-cause mortality.

The mechanism is probably multi-factorial: weight loss in a dyslipidemic population reduces chronic inflammation (lower CRP, IL-6, TNF-α), improves insulin sensitivity, reduces oxidative stress, and may directly engage longevity-associated pathways through AMPK activation and mTOR suppression. GLP-1 receptors are expressed in the hypothalamus, brainstem, pancreas, and peripheral tissues — semaglutide's effects are systemic and genuinely multi-organ.

But the interpretive leap from "this worked in a systemically compromised population" to "this will work in me" requires assumptions not yet supported by data.

HIV-positive adults on antiretrovirals age at accelerated rates across multiple biological clocks. Their epigenetic age is systematically older than chronological age at baseline. Interventions that reduce systemic inflammation in this population produce large clock movements because there is substantial ground to recover. A well-trained 40-year-old with a normal CRP of 0.4 mg/L, healthy fasting glucose, and measured low biological age is starting from a fundamentally different position. The size of the clock effect will not be the same.

A second, separate epigenetic study — the SLIM LIVER trial examining semaglutide in non-alcoholic fatty liver disease — showed similar results in another metabolically compromised population. The pattern is consistent: GLP-1 drugs slow epigenetic aging in men whose biology is meaningfully disrupted. The data for metabolically healthy, lean men does not yet exist.

The Muscle Loss Problem: The Most Underrated Risk for Performance Men#

There is a consequence of GLP-1 therapy that longevity content systematically undersells, and it matters more to the PrimalPrime audience than to the general population.

Across the major clinical trials, approximately 20–40% of total weight lost during GLP-1 RA treatment is lean mass — predominantly skeletal muscle. In STEP-1, where participants on semaglutide lost an average of 14.9% of body weight, the fraction coming from lean tissue was substantial. The mechanism is simple: GLP-1 drugs work by suppressing appetite. A significant calorie deficit, without a deliberate protocol to defend muscle, produces muscle catabolism regardless of the drug involved.

The SEMALEAN study quantified this in obesity patients specifically on semaglutide and found that participants who did not follow a structured resistance program lost a disproportionate amount of lean mass relative to fat. A 2025 prospective study of 200 adults combined semaglutide with resistance training three days per week and ≥2.0 g protein/kg/day, producing approximately 13% total body weight loss with only ~3% loss of muscle mass — a substantially preserved body composition outcome.

For a man whose performance metrics depend on lean mass — VO2 max, power-to-weight ratio, hormonal function, injury resilience — this distinction is decisive. Losing 25–40% of your weight as muscle while simultaneously reducing calorie intake defeats a central goal of performance longevity. The standard guidance to "eat more protein on GLP-1s" understates the protocol required. You need progressive resistance training with measurable overload targets, protein ≥2.0 g/kg body weight distributed across ≥4 feedings, and creatine monohydrate 3–5 g daily to support muscle protein synthesis under energy restriction.

Without this protocol, a GLP-1 drug is net-negative for most performance-focused men in terms of body composition, regardless of what it does to their epigenetic clock.

What GLP-1 Drugs Do to Testosterone#

The testosterone picture depends almost entirely on your starting metabolic state.

In obese or hypogonadal men, GLP-1 receptor agonists produce meaningful and consistent testosterone improvements. A 2024 systematic review found 53–77% increases in total testosterone over 18 months of GLP-1 RA treatment in obese hypogonadal men. The mechanism is indirect: weight loss reduces aromatase activity in adipose tissue (the enzyme that converts testosterone to estrogen), improves insulin sensitivity (which restores hypothalamic-pituitary-gonadal axis signaling), and reduces SHBG-disrupting effects of insulin resistance. These are real testosterone gains driven by metabolic improvement — not a direct pharmacological effect of GLP-1 receptor activation on Leydig cells.

In lean, eugonadal men with normal testosterone levels at baseline, the picture is different. Two studies examining testosterone in GLP-1-treated men without metabolic dysfunction found no meaningful change in free testosterone. Some subjects showed increases in total testosterone, but these were offset by concurrent SHBG elevation — a common side effect of weight loss and caloric restriction. Free testosterone (the bioavailable fraction) remained stable or was mildly reduced.

One additional variable: GLP-1 drugs do not suppress the HPG axis. Unlike exogenous testosterone, they do not reduce LH or FSH, do not suppress testicular function, and do not cause spermatogenic impairment. This is a meaningful distinction for men who are TRT-curious but concerned about fertility.